Evidence for an alternative mechanism for maintaining telomere length in human tumors and tumor-derived cell lines
The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Abstract
The gradual loss of DNA from the ends of telomeres has been implicated in the control of cellular proliferative potential. Telomerase is an enzyme that restores telomeric DNA sequences, and expression of its activity was thought to be essential for the immortalization of human cells, both in vitro and in tumor progression in vivo. Telomerase activity has been detected in 50-100% of tumors of different types, but not in most normal adult somatic tissues. It has also been detected in about 70% of human cell lines immortalized in vitro and in all tumor-derived cell lines examined to date. It has previously been shown that in vitro immortalized telomerase-negative cell lines acquire very long and heterogeneous telomeres in association with immortalization presumably via one or more novel telomere-lengthening mechanisms that we refer to as ALT (alternative lengthening of telomeres). Here we report evidence for the presence of ALT in a subset of tumor-derived cell lines and tumors. The maintenance of telomeres by a mechanism other than telomerase, even in a minority of cancers, has major implications for therapeutic uses of telomerase inhibitors.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“a few rare tumors (29) and some experimentally immortalized cell lines (30) lack detectable telomerase activity.”
From Inhibition of human telomerase in immortal human cells leads to progressive telomere shortening and cell death (1999) · cites this paper as [30]
In the citing paper
“Virally transformed human cells that eliminate p53 and/or pRB function can escape crisis at very low frequencies, and invariably adopt telomere-maintenance programs: 80-90% of human tumors possess some telomerase activity, while the remainder maintain telomeres via a recombination-mediated process termed ALT (for Alternative Lengthening of Telomeres)37-40.”
From Telomere dysfunction and tumour suppression: the senescence connection (2008) · cites this paper as [39]
In the citing paper
“A significant number of human tumours can also maintain telomeres by recombination-based ALT mechanisms in the absence of telomerase 72 .”
From The common biology of cancer and ageing (2007) · cites this paper as [72]
Citations
Cites
Specific Association of Human Telomerase Activity with Immortal Cells and Cancer
Kim, N. W., Piatyszek, M. A., Prowse, K. R., Harley, C. B., West, M. D., Ho, P. L. C., Coviello, G. M., Wright, W. E., Weinrich, S. L., & Shay, J. W. (1994) · Science · doi:10.1126/science.7605428 · Cited by 7,091
Telomeres shorten during ageing of human fibroblasts
Harley, C. B., Futcher, A. B., & Greider, C. W. (1990) · Nature · doi:10.1038/345458a0 · Cited by 5,750
The p53 tumour suppressor gene
Levine, A. J., Momand, J., & Finlay, C. A. (1991) · Nature · doi:10.1038/351453a0 · Cited by 3,788
Identification of a specific telomere terminal transferase activity in tetrahymena extracts
Greider, C. W., & Blackburn, E. H. (1985) · Cell · doi:10.1016/0092-8674(85)90170-9 · Cited by 3,400
Counter, C. M., Avilion, A. A., LeFeuvre, C. E., Stewart, N. G., Greider, C. W., Harley, C. B., & Bacchetti, S. (1992) · The EMBO Journal · doi:10.1002/j.1460-2075.1992.tb05245.x · Cited by 2,096
Telomere reduction in human colorectal carcinoma and with ageing
Hastie, N. D., Dempster, M., Dunlop, M. G., Thompson, A. M., Green, D. K., & Allshire, R. C. (1990) · Nature · doi:10.1038/346866a0 · Cited by 1,650
Telomere elongation in immortal human cells without detectable telomerase activity
Bryan, T. M., Englezou, A., Gupta, J., Bacchetti, S., & Reddel, R. R. (1995) · The EMBO Journal · doi:10.1002/j.1460-2075.1995.tb00098.x · Cited by 1,279
Self-citationTelomere loss: mitotic clock or genetic time bomb?
Harley, C. B. (1991) · Mutation Research/DNAging · doi:10.1016/0921-8734(91)90018-7 · Cited by 1,139
An alternative pathway for yeast telomere maintenance rescues est1− senescence
Lundblad, V., & Blackburn, E. H. (1993) · Cell · doi:10.1016/0092-8674(93)90234-h · Cited by 942
Telomerase activity in human ovarian carcinoma.
Counter, C. M., Hirte, H. W., Bacchetti, S., & Harley, C. B. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.8.2900 · Cited by 677
Cited by
Items 601–700 of 1,000
Telomere lengthening in telomerase-negative cells: the ends are coming together
Scheel, C., & Poremba, C. (2002) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-002-0634-9 · Cited by 32
“Breast carcinoma, Li-Fraumeni syndrome [6] Malignant melanoma [ 6 ] Lung carcinoma [6] Ovarian carcinoma [6] Osteosarcoma [6, 56] Renal carcinoma [39]”
BackgroundInfluentialCellular senescence, telomere recombination and maintenance
Yang, Q. (2008) · Cytogenetic and Genome Research · doi:10.1159/000167806 · Cited by 33
“Fax +41 61 306 12 34 E-Mail karger@karger.ch www.karger.com telomeres (ALT) mechanism (Bryan et al., 1995, 1997).”
Recruitment of NBS1 into PML oncogenic domains via interaction with SP100 protein
Naka, K., Ikeda, K., & Motoyama, N. (2002) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(02)02755-9 · Cited by 36
Telomere Length Regulation—A View from the Individual Chromosome Perspective
Slijepčević, P. (1998) · Experimental Cell Research · doi:10.1006/excr.1998.4185 · Cited by 30
The alternative lengthening of telomeres pathway may operate in non‐neoplastic human cells
Slatter, T. L., Tan, X., Yuen, Y. C., Gunningham, S. P., SiYan, S., Daly, E., Packer, S. G. K., Devenish, C. J., Royds, J. A., & Hung, N. A. (2012) · The Journal of Pathology · doi:10.1002/path.2981 · Cited by 29
Uchida, N., Otsuka, T., Shigematsu, H., Maeda, M., Sugio, Y., Itoh, Y., & Niho, Y. (1999) · Leukemia Research · doi:10.1016/s0145-2126(99)00149-6 · Cited by 27
“Although there are some immortalized cells which can maintain telomere length without demonstrating any detectable telomerase activity [27], telomerase has been shown to play the main role in regulating telomere length.”
BackgroundKumar, M., Lechel, A., & Güneş, Ç. (2016) · Genes · doi:10.3390/genes7080043 · Cited by 30
“As a flaw, however, anti‐telomerase therapy may provoke ALT m chan sm in cancer cells [26].”
BackgroundChromothripsis and telomere crisis: engines of genome instability
Dewhurst, S. M. (2020) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2020.02.009 · Cited by 29
“of cancers this is achieved through telomerase activation, but can also occur through an alternative recombination-based mechanism known as ALT (alternative lengthening of telomeres) [7, 8].”
BackgroundOncohistones and disrupted development in pediatric-type diffuse high-grade glioma
Ocasio, J. K., Budd, K. M., Roach, J. T., Andrews, J. M., & Baker, S. J. (2023) · Cancer and Metastasis Reviews · doi:10.1007/s10555-023-10105-2 · Cited by 33
“Such mutations provide an alternative method of telomere lengthening (ALT), which can prevent growth arrest in immortalized cells [93].”
MethodTelomerase-targeted therapies in myeloid malignancies
Waksal, J. A., Bruedigam, C., Komrokji, R. S., Jamieson, C. H. M., & Mascarenhas, J. O. (2023) · Blood Advances · doi:10.1182/bloodadvances.2023009903 · Cited by 29
“A small but important subset of malignant cells extends their telomeres by telomerase-independent mechanisms (ie, alternative lengthening of telomeres pathway).(35) This is usually observed in mesenchymal tumors originating from bone, soft tissue, and the nervous system.”
BackgroundOrganismal propagation in the absence of a functional telomerase pathway in Caenorhabditis elegans
Lackner, D. H., Raíces, M., Maruyama, H., Haggblom, C., & Karlseder, J. (2012) · The EMBO Journal · doi:10.1038/emboj.2012.61 · Cited by 30
“However, in B 10% of cancers telomerase remains downregulated and telomeres are maintained through a telomerase-independent mechanism called alternative lengthening of telomeres (ALT) (Bryan et al , 1995, 1997).”
Školáková, P., Foldynová-Trantírková, S., Bednářová, K., Fiala, R., Vorlı́čková, M., & Trantı́rek, L. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv296 · Cited by 27
“In these tumours, telomeres are maintained using the homologous recombination (HR)based alternative lengthening of telomeres (ALT) mechanism (17).”
BackgroundMethodNucleostemin inhibits TRF1 dimerization and shortens its dynamic association with the telomere
Meng, L., Hsu, J. K., Zhu, Q., Lin, T., & Tsai, R. Y. L. (2011) · Journal of Cell Science · doi:10.1242/jcs.089672 · Cited by 29
Hsu, C.-P., Lee, L.-W., Shai, S.-E., & Chen, C.-Y. (2005) · World Journal of Gastroenterology · doi:10.3748/wjg.v11.i44.6941 · Cited by 29
BAL31-NGS approach for identification of telomeres de novo in large genomes
Peška, V., Sitová, Z., Fajkus, P., & Fajkus, J. (2016) · Methods · doi:10.1016/j.ymeth.2016.08.017 · Cited by 27
The role of SMARCAL1 in replication fork stability and telomere maintenance
Lugli, N., Sotiriou, S. K., & Halazonetis, T. D. (2017) · DNA repair · doi:10.1016/j.dnarep.2017.06.015 · Cited by 29
Telomerase activation in colorectal carcinogenesis
Yan, P., Saraga, E. P., Bouzourene, H., Bosman, F. T., & Benhattar, J. (1999) · The Journal of Pathology · doi:10.1002/(sici)1096-9896(199910)189:2<207::aid-path424>3.0.co;2-h · Cited by 28
Smits, R., Hofland, N., Edelmann, W., Geugien, M., Jagmohan-Changur, S., Albuquerque, C., Breukel, C., Kucherlapati, R., Kielman, M. F., & Fodde, R. (2000) · Genes, Chromosomes and Cancer · doi:10.1002/1098-2264(2000)9999:9999<::aid-gcc1033>3.0.co;2-r · Cited by 91
Burger, A. M., Fiebig, H., Kuettel, M. R., Lautenberger, J. A., Kung, H. F., & Rhim, J. S. (1998) · International Journal of Oncology · doi:10.3892/ijo.13.5.1043 · Cited by 27
Telomerase Activity In Preleukemia And Acute Myelogenous Leukemia
Li, Y., Yang, J., Andrews, C., Chen, Y., Toofanfard, P., Huang, R., Horvath, E., Chopra, H. K., Raza, A., & Preisler, H. D. (2000) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428190009148406 · Cited by 27
Molecular Pathogenesis of Hodgkin Lymphoma: Past, Present, Future
Bienz, M., Ramdani, S., & Knecht, H. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21186623 · Cited by 28
“described the principle of alternative lengthening of telomeres (ALT), a telomerase-independent pathway able to maintain telomeric length in malignant tumors [52].”
BackgroundGu, W. L., Lin, Z., Zhao, S., Wang, G., Shen, Z., Liu, W., Cai, Y., Wang, K., Wan, C. C., & Yan, T. (2022) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2022/2905663 · Cited by 27
“Besides, there are about 5-10% of cancer cells use alternative lengthening of telomeres (ALT) to maintain telomeres [15].”
BackgroundTERRA and Telomere Maintenance in the Yeast Saccharomyces cerevisiae
Zeinoun, B., Teixeira, M. T., & Barascu, A. (2023) · Genes · doi:10.3390/genes14030618 · Cited by 31
Telomeres rather than telomerase a key target for anti‐cancer therapy?
Boukamp, P., & Mirancea, N. (2006) · Experimental Dermatology · doi:10.1111/j.1600-0625.2006.00517.x · Cited by 26
Telomerase activation in a model of lung adenocarcinoma
Suau, F., Cottin, V., Archer, F., Croze, S., Chastang, J., Cordier, G., Thivolet-Béjui, F., Mornex, J., & Leroux, C. (2006) · European Respiratory Journal · doi:10.1183/09031936.06.00125105 · Cited by 26
Wang, H., Zhang, K., Liu, Y., Fu, Y., Gao, S., Gong, P., Wang, H., Zhou, Z., Zeng, M., Wu, Z., et al. (2017) · BMC Biology · doi:10.1186/s12915-017-0453-8 · Cited by 27
“and particularly those positive for alternative lengthening of telomeres (ALT), are characterized by remarkable telomere length heterogeneity [6].”
Cairney, C. J., Hoare, S. F., Daidone, M. G., Zaffaroni, N., & Keith, W. N. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604328 · Cited by 28
“However, telomere length maintenance can also be achieved in some tumour types in the absence of telomerase activity through an alternative recombination-based mechanism termed ALT (alternative lengthening of telomeres) (Bryan et al, 1995, 1997).”
BackgroundTelomere Biology of Human Hematopoietic Stem Cells
Elwood, N. J. (2004) · Cancer Control · doi:10.1177/107327480401100214 · Cited by 36
In vitro expansion of mammalian telomere repeats by DNA polymerase alpha-primase
Nozawa, K., Suzuki, M., Takemura, M., & Yoshida, S. (2000) · Nucleic Acids Research · doi:10.1093/nar/28.16.3117 · Cited by 28
Telomeres and telomerase: targets for cancer chemotherapy?
Perry, P. J., & Kèlland, L. R. (1998) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.8.12.1567 · Cited by 29
Lee, J. H., Jeong, S. A., Khadka, P., Hong, J., & Chung, I. K. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv844 · Cited by 32
“To measure the telomere length, genomic DNA was isolated from HeLa S3 cells stably expressing SRSF11 shRNAs or control shRNA using the GenElute kit (Sigma-Aldrich), digested with Hinf1 and Rsa1 and separated on 1% agarose gel as described previously (37).”
BackgroundInfluentialSwi1Timeless Prevents Repeat Instability at Fission Yeast Telomeres
Gadaleta, M. C., Das, M. M., Tanizawa, H., Chang, Y.-T., Noma, K.-I., Nakamura, T., & Noguchi, E. (2016) · PLoS Genetics · doi:10.1371/journal.pgen.1005943 · Cited by 26
“However, a strikingly higher proportion of swi1Δ est1Δ strains developed long and heterogeneous telomeres (Fig 8A and 8B), a feature reminiscent of ALT activation in humans [94, 95] and type-II survivors in S.”
BackgroundClaussin, C., & Chang, M. (2016) · PLoS Genetics · doi:10.1371/journal.pgen.1006176 · Cited by 27
“The remaining 10 – 15% of cancers employ telomerase-independent, recombination-based mechanisms, collectively termed alternative lengthening of telomeres (ALT) [8].”
XPF activates break-induced telomere synthesis
Guh, C.-Y., Shen, H.-J., Chen, L. W., Chiu, P.-C., Liao, I.-H., Lo, C.-C., Chen, Y., Hsieh, Y.-H., Chang, T.-C., Yen, C.-P., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-33428-0 · Cited by 28
ATRX/DAXX: Guarding the Genome against the Hazards of ALT
Soper, S. F. C., & Meltzer, P. S. (2023) · Genes · doi:10.3390/genes14040790 · Cited by 27
Li, F., Wang, Y., Hwang, I., Jang, J.-Y., Xu, L., Deng, Z., Yu, E. Y., Cai, Y., Wu, C., Han, Z., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-37480-2 · Cited by 28
Gupta, S. V., Campos, L., & Schmidt, K. H. (2023) · Genetics · doi:10.1093/genetics/iyad147 · Cited by 27
HIRA protects telomeres against R-loop-induced instability in ALT cancer cells
Lynskey, M. L., Brown, E. E., Bhargava, R., Wondisford, A. R., Ouriou, J.-B., Freund, O., Bowman, R. W., Smith, B. A., Lardo, S. M., Schamus, S., et al. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.114964 · Cited by 28
Differential nuclear ATRX expression in sarcomas
Koelsche, C., Renner, M., Johann, P. D., Leiss, I., Sahm, F., Schimmack, S. J., Wardelmann, E., Renker, E.-K., Schirmacher, P., Korshunov, A., et al. (2015) · Histopathology · doi:10.1111/his.12812 · Cited by 26
“Thus, these data support mechanistic considerations regarding an ATRX loss and ALT in mesenchymal tumours in general, as already described for some other human malignancies.(5,6,17,23) A”
ResultTelomere dysfunction is related to the intrinsic radio-resistance of human oral cancer cells
McCaul, J. A., Gordon, K., Minty, F., Fleming, J., & Parkinson, E. K. (2007) · Oral Oncology · doi:10.1016/j.oraloncology.2007.02.010 · Cited by 28
Wu, X., & Tanaka, H. (2015) · Oncotarget · doi:10.18632/oncotarget.5083 · Cited by 28
“One possible explanation of these false negative results could be involvement of ALT (alternative lengthening mechanisms of telomeres) pathway in which tumors often have heterogeneous telomere length with relatively longer telomeres [57].”
Suraweera, N., Mouradov, D., Li, S., Jorissen, R. N., Hampson, D., Ghosh, A., Sengupta, N., Thaha, M. A., Ahmed, S., Kirwan, M., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.9015 · Cited by 29
“The first molecular details of ALT in human tumor cells.”
BackgroundInfluentialDysfunctional telomeres and hematological disorders
Fiorini, E., Santoni, A., & Colla, S. (2018) · Differentiation · doi:10.1016/j.diff.2018.01.001 · Cited by 26
“Eventually telomerase reactivation or activation of the ALT pathway, which restores Differentiation.”
BackgroundInfluentialDahlgren, P. N., Bishop, K., Dey, S., Herbert, B., & Tanaka, H. (2018) · Neoplasia · doi:10.1016/j.neo.2018.02.007 · Cited by 27
“In many cases of human cancers, telomerase activation is responsible for stable telomere maintenance; however, 5% to 15% of cases (which depend on cancer types) are associated with an alternative mechanism termed ALT (alternative lengthening of telomeres) [22].”
BackgroundRoles of RAD 51 and RTEL 1 in telomere and rDNA stability in Physcomitrella patens
Goffová, I., Vágnerová, R., Peška, V., Franek, M., Havlová, K., Holá, M., Zachová, D., Fojtová, M., Cuming, A. C., Kamisugi, Y., et al. (2019) · The Plant Journal · doi:10.1111/tpj.14304 · Cited by 27
Jackson, M. R., Bavelaar, B. M., Waghorn, P. A., Gill, M. R., El-Sagheer, A. H., Brown, T., Tarsounas, M., & Vallis, K. A. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-3594 · Cited by 26
“The osteosarcoma cell line, U2OS, was found to lack detectable telomerase activity in the TRAP assay, as described previously (27).”
ALT: A Multi-Faceted Phenomenon
Sommer, A., & Royle, N. J. (2020) · Genes · doi:10.3390/genes11020133 · Cited by 26
“an alternative lengthening of telomeres (ALT) mechanism [7].”
BackgroundMaintenance of Yeast Genome Integrity by RecQ Family DNA Helicases
Gupta, S. V., & Schmidt, K. H. (2020) · Genes · doi:10.3390/genes11020205 · Cited by 26
Kim, E., Kim, J., Kim, C., & Lee, J. (2021) · Nucleic Acids Research · doi:10.1093/nar/gkab141 · Cited by 28
Huang, J. J., Lin, M. C. M., Bai, Y. X., Jing, D. D., Wong, B. C. Y., Han, S. W., Lin, J., Xu, B., Huang, C., & Kung, H. (2002) · PubMed · Cited by 28
Telomere Recombination Accelerates Cellular Aging in Saccharomyces cerevisiae
Chen, X., Meng, F., & Zhou, J. (2009) · PLoS Genetics · doi:10.1371/journal.pgen.1000535 · Cited by 29
“Because type II survivors have long and heterogeneous PLoS Genetics | www.plosgenetics.org 1 June 2009 | Volume 5 | Issue 6 | e1000535 telomeric repeats, and their telomere maintenance requires both RAD50 and RAD52, they resemble human ALT cells [20,23–25].”
InfluentialCellular lifespan and regenerative medicine
Petersen, T. H., & Niklason, L. E. (2007) · Biomaterials · doi:10.1016/j.biomaterials.2007.05.012 · Cited by 30
“telomeric repeat amplification protocol) together with telomere lengths ranging from short to very long in replicating cells [44].”
Backgroundda Costa, C., Egeler, R. M., Hoogeboom, M., Szuhai, K., Forsyth, R. G., Niesters, M., de Krijger, R. R., Tazi, A., Hogendoorn, P. C. W., & Annels, N. E. (2007) · The Journal of Pathology · doi:10.1002/path.2167 · Cited by 25
“In contrast, pathological telomere elongation is found in a large majority of cancers, either via telomerase enzymatic activity or by an alternative telomerase-independent pathway thought to involve homologous recombination, known as alternative lengthening of telomeres (ALT) [18–20].”
BackgroundKim, S. H., Chung, H. K., Kang, J. H., Kim, K. I., Jeon, Y. H., Jin, Y. N., Yun, C., & Chung, J.-K. (2008) · Human Gene Therapy · doi:10.1089/hgt.2008.030 · Cited by 25
Telomeric and interstitial telomeric-like DNA sequences in Orthoptera genomes
López‐Fernández, C., Pradillo, E., Zabal‐Aguirre, M., Fernández, J. L., de la Vega, C. G., & Gosálvez, J. (2004) · Genome · doi:10.1139/g03-143 · Cited by 25
“Moreover, this mechanism has been invoked to explain the maintenance of telomere length in the absence of telomerase activity (Bryan et al. 1997).”
BackgroundMochida, A., Gotoh, E., Senpuku, H., Harada, S., Kitamura, R., Takahashi, T., & Yanagi, K. (2005) · Archives of Virology · doi:10.1007/s00705-005-0557-2 · Cited by 25
“cells like human fibroblast-derived cells [8, 11, 51, 64] and some tumors and tumor-derived cell lines [ 7 ].”
BackgroundShammas, M. A., Liu, X., Gavory, G., Raney, K. D., Balasubramanian, S., & Reis, R. J. S. (2004) · Experimental Cell Research · doi:10.1016/j.yexcr.2004.01.003 · Cited by 26
Telomerase activation in human fibroblasts during escape from crisis
Montalto, M., Phillips, J. S., & Ray, F. A. (1999) · Journal of Cellular Physiology · doi:10.1002/(sici)1097-4652(199907)180:1<46::aid-jcp5>3.0.co;2-k · Cited by 31
hTERT expression in sporadic renal cell carcinomas
Paradis, V., Bièche, I., Dargère, D., Bonvoust, F., Ferlicot, S., Olivi, M., Lagha, N. B., Blanchet, P., Benoît, G., Vidaud, M., et al. (2001) · The Journal of Pathology · doi:10.1002/path.917 · Cited by 27
“These results indicate that telomerase is not a universal pathway for cells to acquire immortalization in renal tumours, and that a telomerase-independent mechanism might be involved for lengthening telomeres in a subset of renal tumours [45].”
BackgroundFolini, M., Marco, C. D., Orlandi, L., Daidone, M. G., & Zaffaroni, N. (2000) · European Journal of Cancer · doi:10.1016/s0959-8049(00)00295-1 · Cited by 25
“Such a ®nding might be tentatively explained by the emergence of resistant cells through the activation of ALT (alternative lengthening of telomeres) mechanisms, which are responsible for the maintenance of telomeres and have been demonstrated to be present in a few tumours [32], even though our ribozyme transfectant…”
BackgroundThe role of SUMOylation in biomolecular condensate dynamics and protein localization
Gutierrez-Morton, E., & Wang, Y. (2024) · Cell Insight · doi:10.1016/j.cellin.2024.100199 · Cited by 28
“However, 10% – 15% of cancer cells, such as sarcomas and soft tissue tumors, rely on a TMM-independent mechanism, termed the alternative lengthening telomeres (ALT) pathway for telomere elongation (Bryan et al., 1997; Dilley & Greenberg, 2015).”
BackgroundExperience with peritoneal mesothelioma at the Milan National Cancer Institute
D, M. D. M. (2010) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v2.i2.76 · Cited by 24
Martinez, A. R., Kaul, Z., Parvin, J. D., & Groden, J. L. (2017) · Genes Chromosomes and Cancer · doi:10.1002/gcc.22465 · Cited by 24
Telomere Maintenance and the cGAS-STING Pathway in Cancer
Ebata, H., Loo, T. M., & Takahashi, A. (2022) · Cells · doi:10.3390/cells11121958 · Cited by 29
Macha, S. J., Koneru, B., Burrow, T. A., Zhu, C., Savitski, D., Rahman, R. L., Ronaghan, C. A., Nance, J., McCoy, K., Eslinger, C. R., et al. (2022) · Cancer Research · doi:10.1158/0008-5472.can-22-0125 · Cited by 28
POT1 mutations cause differential effects on telomere length leading to opposing disease phenotypes
Zade, N. H., & Khattar, E. (2023) · Journal of Cellular Physiology · doi:10.1002/jcp.31034 · Cited by 27
Fernandes, R. V., & Lingner, J. (2023) · Nucleic Acids Research · doi:10.1093/nar/gkad448 · Cited by 25
Bollmann, F. M. (2013) · Biochimie · doi:10.1016/j.biochi.2013.07.031 · Cited by 31
“recombination-based alternative lengthening of telomeres (ALT) mechanism(s) [13], the physiological significance of which is a”
BackgroundDatar, R. H., Naritoku, W. Y., Li, P., Tsao-Wei, D. D., Groshen, S. G., Taylor, C. R., & Imam, S. A. (1999) · Gynecologic Oncology · doi:10.1006/gyno.1999.5506 · Cited by 24
Smirnova, A., Gamba, R., Khoriauli, L., Vitelli, V., Nergadze, S. G., & Giulotto, E. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2013.00115 · Cited by 26
“In ALT cells, telomere maintenance is due to a recombination based mechanism (Bryan et al., 1997) causing great intracellular variability of telomere length (Henson et al.”
BackgroundStudying telomere replication by Q-CO-FISH: the effect of telomestatin, a potent G-quadruplex ligand
Arnoult, N., Shin‐ya, K., & Londoño‐Vallejo, A. (2008) · Cytogenetic and Genome Research · doi:10.1159/000167808 · Cited by 24
“Cells using ALT (for A lternative L engthening of T elomeres) mechanisms do have long telomeres (Bryan et al., 1997).”
Gan, Y., Mo, Y., Johnston, J. S., Lu, J. L., Wientjes, M. G., & Au, J. L. ‐. (2002) · FEBS Letters · doi:10.1016/s0014-5793(02)03141-1 · Cited by 26
Zheng, X., Mu, G., Zhong, Y.-F., Zhang, T., Cao, Q., Ji, L., Zhao, Y. B., & Mao, Z. (2016) · Chemical Communications · doi:10.1039/c6cc08254h · Cited by 24
Padmanabhan, P., Otero, J. E., Ray, P., Paulmurugan, R., Hoffman, A. R., Gambhir, S. S., Biswal, S., & Ulaner, G. A. (2006) · PubMed · Cited by 25
Blagoev, K. B., & Goodwin, E. H. (2007) · DNA repair · doi:10.1016/j.dnarep.2007.09.012 · Cited by 26
Brachner, A., Sasgary, S., Pirker, C., Rodgarkia‐Dara, C., Mikula, M., Mikulits, W., Bergmeister, H., Setinek, U., Wieser, M., Chin, S., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2839 · Cited by 24
“An alternative telomere lengthening (ALT) mechanism has been described for cancer cells lacking TA (4, 5, 16 , 17).”
BackgroundResultInfluentialTelomere biology in aging and cancer: early history and perspectives
Hayashi, M. (2017) · Genes & Genetic Systems · doi:10.1266/ggs.17-00010 · Cited by 25
Pervasive promoter hypermethylation of silenced TERT alleles in human cancers
Esopi, D., Graham, M. K., Brosnan‐Cashman, J. A., Meyers, J. L., Vaghasia, A. M., Gupta, A. K., Kumar, B., Haffner, M. C., Heaphy, C. M., Marzo, A. M. D., et al. (2020) · Cellular Oncology · doi:10.1007/s13402-020-00531-7 · Cited by 22
Kunieda, J., Yamashita, K., Togashi, Y., Baba, S., Sakata, S., Inamura, K., Ae, K., Matsumoto, S., Machinami, R., Kitagawa, M., et al. (2021) · Cancer Science · doi:10.1111/cas.15256 · Cited by 27
“19 It exhibits the reciprocal translocation, t(12;16)(q13;p11), in approximately 95% of patients, which results in the fusion of FUS- DDIT3, and t(12;22) (q13;q12) in nearly 5% of patients, resulting in the formation of EWSR1- DDIT3.”
BackgroundInterrogating the Genomic Landscape of Uterine Leiomyosarcoma: A Potential for Patient Benefit
Dall, G., Hamilton, A. L., Ratnayake, G., Scott, C. L., & Barker, H. E. (2022) · Cancers · doi:10.3390/cancers14061561 · Cited by 26
Misino, S., Busch, A., Wagner, C. B., Bento, F., & Luke, B. (2022) · Nucleic Acids Research · doi:10.1093/nar/gkac1125 · Cited by 24
“On the other hand, 10–15% of human cancers use an HDR-mediated TMM, that is referred to as the alternative lengthening of telomeres (ALT) mechanism (17,18).”
BackgroundTERRA R-loops connect and protect sister telomeres in mitosis
Sze, S., Bhardwaj, A., Fnu, P., Azarm, K., Mund, R., Ring, K., & Smith, S. H. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.113235 · Cited by 23
Telomeres and aging: on and off the planet!
Mason, C. E., Sierra, M. A., Feng, H. J., & Bailey, S. M. (2024) · Biogerontology · doi:10.1007/s10522-024-10098-7 · Cited by 26
“…cancers lacking telomerase activity maintain telomere length via the recom-bination-mediated Alternative Lengthening of Tel-omeres (ALT) pathway (Bryan et al. 1997; Murnane et al. 1994), which is strongly associated with functional loss of the ATRX-DAXX chromatin-remode-ling complex (Graham et…”
BackgroundEpigenetic Regulation of Telomere Chromatin Integrity in Pluripotent Embryonic Stem Cells
Wong, L. H. (2010) · Epigenomics · doi:10.2217/epi.10.49 · Cited by 23
Telomere Visualization in Tissue Sections using Pyrrole–Imidazole Polyamide Probes
Sasaki, A., Ide, S., Kawamoto, Y., Bando, T., Murata, Y., Shimura, M., Yamada, K., Hirata, A., Nokihara, K., Hirata, T., et al. (2016) · Scientific Reports · doi:10.1038/srep29261 · Cited by 25
Synthetic lethality of cytolytic HSV-1 in cancer cells with ATRX and PML deficiency
Han, M., Napier, C. E., Frölich, S., Teber, E., Wong, T., Noble, J. R., Choi, E. H. Y., Everett, R. D., Cesare, A. J., & Reddel, R. R. (2019) · Journal of Cell Science · doi:10.1242/jcs.222349 · Cited by 25
Self-citationALTernative Functions for Human FANCM at Telomeres
Domingues-Silva, B., Silva, B. D. R., & Azzalin, C. M. (2019) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2019.00084 · Cited by 24
Integrated evaluation of telomerase activation and telomere maintenance across cancer cell lines
Hu, K., Ghandi, M., & Huang, F. W. (2021) · eLife · doi:10.7554/elife.66198 · Cited by 27
Exploring the Structures and Functions of Macromolecular SLX4-Nuclease Complexes in Genome Stability
Payliss, B. J., Patel, A., Sheppard, A. C., & Wyatt, H. D. M. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2021.784167 · Cited by 25
CARF: An emerging regulator of p53 tumor suppressor and senescence pathway
Cheung, C., Hasan, M. K., Widodo, N., Kaul, S. C., & Wadhwa, R. (2008) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2008.05.002 · Cited by 26
Bocchetta, M., & Carbone, M. (2004) · Oncogene · doi:10.1038/sj.onc.1207855 · Cited by 32
Zheng, Y., Zhou, X., Loffredo, C. A., Shields, P. G., & Sun, B. (2010) · Human Molecular Genetics · doi:10.1093/hmg/ddq461 · Cited by 27
“Because greater telomere length variation among chromosomal telomeres is one of the characteristics of cancer cells that use alternative lengthening of telomeres (ALT) to maintain the telomere length (17,18), we hypothesized that greater telomere length variation between homologous telomeres confers telomere instabili…”
BackgroundSenescence as a modulator of oral squamous cell carcinoma development
Parkinson, E. K. (2010) · Oral Oncology · doi:10.1016/j.oraloncology.2009.09.009 · Cited by 26
M’kacher, R., Cuceu, C., Jawhari, M. A., Morat, L., Frenzel, M., Shim, G., Lenain, A., Hempel, W. M., Junker, S., Girinsky, T., et al. (2018) · Cancers · doi:10.3390/cancers10060169 · Cited by 24
“The most reliable methods for detecting ALT in tumor samples or cell lines are assays that assess the formation of APBs [10,29], the presence of C-circles [11], the heterogeneity of telomere lengths [36], or the presence of T-SCE.”
MethodClinical implications of telomerase detection
Matthews, P., & Jones, C. J. (2001) · Histopathology · doi:10.1046/j.1365-2559.2001.01186.x · Cited by 23
“Pathological telomerase activity is also detected in the majority of malignant tumours,(5) although some tumours may maintain their telomeres in a telomerase-independent manner.(6) Two routes to a telomerase-positive tumour may be envisaged.”
BackgroundTelomere Structure, Replication and Length Maintenance
Muniyappa, K., & Kironmai, K. M. (1998) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.1080/10409239891204242 · Cited by 24
Pizzul, P., Rinaldi, C., & Bonetti, D. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2023.1250264 · Cited by 27
“Nonetheless, in yeast andmammals, homology-directed DNA repair (HDR) mechanisms constitute a TMM besides telomerase enzyme (Lundblad and Blackburn, 1993; Bryan et al., 1997; Sobinoff and Pickett, 2017).”
BackgroundImmortalized cells as experimental models to study cancer
Boehm, J. S., & Hahn, W. C. (2004) · Cytotechnology · doi:10.1007/s10616-004-5125-1 · Cited by 28
Piqueret‐Stephan, L., Ricoul, M., Hempel, W. M., & Sabatier, L. (2016) · Scientific Reports · doi:10.1038/srep32510 · Cited by 24
TERT-mediated and ATRX-mediated Telomere Maintenance and Neuroblastoma
Duan, X., & Zhao, Q. (2017) · Journal of Pediatric Hematology/Oncology · doi:10.1097/mph.0000000000000840 · Cited by 26
Metadata
- Authors
- Bryan, T. M., Englezou, A., Dalla-Pozza, L., Dunham, M. A., & Reddel, R. R.
- Affiliations
- Children's Medical Research Institute (AU)
- Corresponding author
- Reddel, Roger R.
- Venue
- Nature Medicine
- Published
- 1997-11
- Volume
- 3
- Issue
- 11
- Pages
- 1271-1274
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- OpenAlex
- W2013073993
- Cited by
- 1,292
- References
- 39
- Citations by year
- 2026: 19 · 2025: 41 · 2024: 37 · 2023: 48 · 2022: 31 · 2021: 34 · 2020: 44 · 2019: 52 · 2018: 27 · 2017: 54 · 2016: 35 · 2015: 52 · 2014: 33 · 2013: 52 · 2012: 39
- FWCI
- 27.26
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Telomeres, Telomerase, and Senescence
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Aging › Genetics, Aging, and Longevity in Model Organisms
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › DNA and Nucleic Acid Chemistry
- Keywords
- alternative lengthening of telomeres, telomere maintenance, telomerase, tumor-derived cell lines, cell immortalization, telomerase inhibitors, cancer therapy, telomere loss
- MeSH terms
- Adult, DNA Nucleotidyltransferases, Humans, Neoplasms, Tumor Cells, Cultured, Deoxyribonucleases, Type II Site-Specific, Telomere, Telomerase
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.